Kevin Koch's most recent trade in Edgewise Therapeutics Inc was a trade of 525,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Aug. 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2025 | 525,000 | 525,000 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2025 | 87,500 | 87,500 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2025 | 17,968 | 38,587 | - | 0 | Common Stock | |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2025 | 17,968 | 53,907 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.39 per share. | 12 Aug 2025 | 7,972 | 30,615 | - | 13.4 | 106,764 | Common Stock |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 10,417 | 24,895 | - | 0 | Common Stock | |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2025 | 10,417 | 0 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 16.45 per share. | 01 May 2025 | 4,276 | 20,619 | - | 16.5 | 70,358 | Common Stock |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.18 per share. | 07 Mar 2025 | 100 | 14,578 | - | 0.2 | 18 | Common Stock |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 100 | 41,545 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 07 Mar 2025 | 100 | 14,478 | - | 30 | 3,000 | Common Stock |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.18 per share. | 05 Feb 2025 | 8,636 | 23,114 | - | 0.2 | 1,554 | Common Stock |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 30.03 per share. | 05 Feb 2025 | 8,636 | 14,478 | - | 30.0 | 259,298 | Common Stock |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2025 | 8,636 | 42,545 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.11 per share. | 05 Feb 2025 | 900 | 15,378 | - | 13.1 | 11,799 | Common Stock |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 31.13 per share. | 05 Feb 2025 | 900 | 14,478 | - | 31.1 | 28,018 | Common Stock |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2025 | 900 | 41,645 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 431,250 | 431,250 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 71,875 | 71,875 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 10,417 | 10,417 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2024 | 10,417 | 17,630 | - | 0 | Common Stock | |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 18.91 per share. | 01 May 2024 | 3,152 | 14,478 | - | 18.9 | 59,604 | Common Stock |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 10,416 | 20,834 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2023 | 10,416 | 10,416 | - | 0 | Common Stock | |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 8.90 per share. | 01 May 2023 | 3,203 | 7,213 | - | 8.9 | 28,522 | Common Stock |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Aug 2022 | 550,000 | 550,000 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2022 | 31,250 | 31,250 | - | - | Restricted Stock Units | |
| Edgewise Therapeutics Inc | Kevin Koch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) |